Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 2Recruiting 2Completed 2Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 11Plasma cell 4Other hematologic neoplasm 3Dermatologic 3Other solid neoplasm 2CNS 2Thoracic 1Sarcoma 1Genitourinary 1Breast 1

Conditions

Sarcoma 1Osteosarcoma 1Melanoma 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1Breast Neoplasms 1Bone Neoplasms 1

Interventions

Paclitaxel 83Fulvestrant 65Trastuzumab 62Letrozole 61pembrolizumab 53Carboplatin 51Cyclophosphamide 48pertuzumab 46palbociclib 44Anastrozole 41Capecitabine 33Tamoxifen 30Magnetic Resonance Spectroscopy 29exemestane 28Radiotherapy 28Doxorubicin 28ribociclib 26olaparib 26Docetaxel 26Specimen Handling 25abemaciclib 24130-nm albumin-bound paclitaxel 20trastuzumab deruxtecan 19Taxes 19Gemcitabine 19durvalumab 18Surveys and Questionnaires 18Epirubicin 18eribulin 17Alpelisib 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × tocilizumab × Breast × Clear all
NCT04616248 2026-01-07

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

University of Southern California

Phase 1 Active not recruiting
14 enrolled
BreastDermatologicSarcoma

Bone Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Melanoma, Sarcoma, Osteosarcoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡